BioTech
-
Grail, Stealth, Alnylam and more
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Grail plan for evaluating its Galleri cancer liquid biopsy challenged- STAT
A new analysis published Sunday challenges the clinical trial endpoint the cancer screening firm Grail is using to evaluate its…
Read More » -
Alnylam drug lowered blood pressure when combined with pills
ATLANTA — New trial results show that a drug candidate from Alnylam Pharmaceuticals can lead to long-lasting blood pressure reduction…
Read More » -
Readout Newsletter: Sanofi, Oruka, Caribou Biosciences
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
U.K. decision on ALS drug has neurologists, advocates up in arms
LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that…
Read More » -
32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second quarter and middle of the…
Read More » -
Boehringer layoffs tied to disappointing Humira biosimilar sales
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of…
Read More » -
Verve Therapeutics ‘pauses’ tests of its gene editor for heart disease
Verve Therapeutics said Tuesday that it is pausing testing of its closely watched gene-editing treatment for high cholesterol after a…
Read More » -
Amylyx did the right thing by pulling ALS drug. That’s rare and worthy of praise
On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after a large clinical trial showed…
Read More » -
Weed for weight loss, and more in biotech
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to…
Read More »